2024
Competing risk analysis to estimate amputation incidence and risk in lower-extremity peripheral artery disease
Callegari S, Smolderen K, Cleman J, Mena-Hurtado C, Romain G. Competing risk analysis to estimate amputation incidence and risk in lower-extremity peripheral artery disease. Vascular Medicine 2024, 29: 496-506. PMID: 39219174, DOI: 10.1177/1358863x241268727.Peer-Reviewed Original ResearchChronic limb-threatening ischemiaAmputation riskTime-to-event analysisPeripheral arterial diseaseLower-extremity peripheral arterial diseaseCumulative incidence functionCompeting risk analysisAmputation incidenceAmputation dataMedicare claimsLimb-threatening ischemiaVascular Quality Initiative registryMortality riskOutcomes researchPeripheral vascular interventionsArtery diseaseAmputationVascular outcomesCox regressionRiskMortalityCohortVascular interventionsTime-to-event methodsPatientsPAIN PROFILES IN PATIENTS WITH PERIPHERAL ARTERY DISEASE: ROLE OF PSYCHOSOCIAL FACTORS AND FEMALE SEX
Alashi A, Hurtado C, Romain G, Callegari S, Jacque F, Sinusas A, Smolderen K. PAIN PROFILES IN PATIENTS WITH PERIPHERAL ARTERY DISEASE: ROLE OF PSYCHOSOCIAL FACTORS AND FEMALE SEX. Journal Of The American College Of Cardiology 2024, 83: 2284. DOI: 10.1016/s0735-1097(24)04274-8.Peer-Reviewed Original ResearchImpact of comorbid opioid use disorder and major depressive disorder on healthcare utilization outcomes in patients with peripheral artery disease: A National Readmission Database analysis
Amenyedor K, Lee M, Algara M, Siddiqui W, Hardt M, Romain G, Mena-Hurtado C, Smolderen K. Impact of comorbid opioid use disorder and major depressive disorder on healthcare utilization outcomes in patients with peripheral artery disease: A National Readmission Database analysis. Vascular Medicine 2024, 29: 163-171. PMID: 38391134, DOI: 10.1177/1358863x241228540.Peer-Reviewed Original ResearchComorbid opioid use disorderOpioid use disorderPeripheral arterial diseaseDepressive disorderUse disorderArtery diseaseHealthcare utilization outcomesICD-9/10 diagnosis codesPain management strategiesMultivariate logistic regression modelNational Readmission DatabaseHierarchical multivariable logistic regression modelsLength of stayLogistic regression modelsMDDMedian stayPrimary outcomeHighest median costReadmissions DatabasePatientsMedian costStudy populationUtilization outcomesWeighted admissionsDiagnosis codes
2023
A state-of-the-art review of quality-of-life assessment in venous disease
Cleman J, Xia K, Haider M, Nikooie R, Scierka L, Romain G, Attaran R, Grimshaw A, Mena-Hurtado C, Smolderen K. A state-of-the-art review of quality-of-life assessment in venous disease. Journal Of Vascular Surgery Venous And Lymphatic Disorders 2023, 12: 101725. PMID: 38128828, PMCID: PMC11523418, DOI: 10.1016/j.jvsv.2023.101725.Peer-Reviewed Original ResearchDisease-specific patient-reported outcome measurePatient-reported outcome measuresChronic venous diseaseCharing Cross Venous Ulcer QuestionnaireChronic Venous Insufficiency QuestionnaireVenous diseaseHealth statusVenous ulcersEvidence baseRelevant English-language studiesPatients' health statusContent validityEnglish-language studiesFull-text articlesManifestations of diseaseC6 diseaseOvid EmbaseInclusion criteriaOutcome measuresCommon conditionClinical settingDiseaseLiterature searchPatientsUlcersPatient knowledge and preferences for peripheral artery disease treatment
Smolderen K, Romain G, Gosch K, Arham A, Provance J, Spertus J, Poosala A, Shishehbor M, Safley D, Scott K, Stone N, Mena-Hurtado C. Patient knowledge and preferences for peripheral artery disease treatment. Vascular Medicine 2023, 28: 397-403. PMID: 37638882, PMCID: PMC10591804, DOI: 10.1177/1358863x231181613.Peer-Reviewed Original ResearchPeripheral artery diseaseTreatment goalsPatient knowledgeTreatment optionsTreatment preferencesHeart attack/strokeSymptomatic peripheral artery diseasePeripheral artery disease treatmentImportant treatment goalQuality of lifeCost of treatmentSpecific treatment goalsMulticenter registryPAD symptomsPain reliefSecondary preventionArtery diseaseTreatment choiceTreatment benefitPatient understandingPatientsMedical decision makingDisease managementClaudicationDisease treatmentRepresentativeness of Peripheral Artery Disease Randomized Clinical Trials Supporting Current Guidelines
Castro-Dominguez Y, Mena-Hurtado C, Algara M, Obas V, Ahmed Z, Romain G, Solaru K, Smolderen K. Representativeness of Peripheral Artery Disease Randomized Clinical Trials Supporting Current Guidelines. The American Journal Of Cardiology 2023, 201: 166-169. PMID: 37385170, DOI: 10.1016/j.amjcard.2023.05.053.Peer-Reviewed Original ResearchConceptsPeripheral artery diseasePAD guidelinesArtery diseaseRecent American Heart Association/American CollegeAmerican Heart Association/American CollegeLower extremity peripheral artery diseaseOlder adult patientsRace/ethnicity distributionAdult patientsPooled proportionMean ageClinical trialsCurrent guidelinesEpidemiologic studiesAmerican CollegeTrial participantsRCTsEthnicity distributionOlder adultsTrialsWomenPatientsDiseaseGuidelinesEthnic groupsDrug‐Coated Balloon and Drug‐Eluting Stent Safety in Patients With Femoropopliteal and Severe Chronic Kidney Disease
Hanna J, Smolderen K, Castro‐Dominguez Y, Romain G, Lee M, Turner J, Mena‐Hurtado C. Drug‐Coated Balloon and Drug‐Eluting Stent Safety in Patients With Femoropopliteal and Severe Chronic Kidney Disease. Journal Of The American Heart Association 2023, 12: e028622. PMID: 36974774, PMCID: PMC10122876, DOI: 10.1161/jaha.122.028622.Peer-Reviewed Original ResearchConceptsEarly-stage chronic kidney diseaseChronic kidney diseaseBare metal stentsDrug-eluting stentsDrug-coated balloonsMortality riskAmputation riskKidney diseaseSevere chronic kidney diseaseMajor amputation riskPlain balloon angioplastyDrug-Coated BalloonAmputation outcomesCKD statusAmputation rateCause mortalityBackground PatientsAdjusted analysisBalloon angioplastyFemoropopliteal interventionsDES useBMS useRegistry dataDisease trialsPatientsCommunity distress and risk of adverse outcomes after peripheral vascular intervention
Schenck C, Strand E, Smolderen K, Romain G, Nagpal S, Cleman J, Blume P, Mena-Hurtado C. Community distress and risk of adverse outcomes after peripheral vascular intervention. Journal Of Vascular Surgery 2023, 78: 166-174.e3. PMID: 36944389, PMCID: PMC11146282, DOI: 10.1016/j.jvs.2023.03.027.Peer-Reviewed Original ResearchConceptsPeripheral vascular interventionsDistressed Communities IndexMajor amputationRisk of mortalityAdverse outcomesVascular interventionsVascular Quality Initiative databaseDCI scoresCommunity distressCox regression modelTime-dependent receiverCharacteristic curve analysisClinical characteristicsFinal cohortPrimary outcomeClinical outcomesCardiovascular diseasePatientsAmputationZip code dataMortalityRisk categoriesCurve analysisInitiative databaseOutcomesUse of drug-coated balloons and stents in patients with femoropopliteal artery disease and severe chronic kidney disease
Castro-Dominguez Y, Smolderen K, Romain G, Turner J, Mena-Hurtado C. Use of drug-coated balloons and stents in patients with femoropopliteal artery disease and severe chronic kidney disease. Vascular Medicine 2023, 28: 150-152. PMID: 36710497, DOI: 10.1177/1358863x221148521.Peer-Reviewed Original Research
2022
The shifting care and outcomes for patients with endangered limbs – Critical limb ischemia (SCOPE-CLI) registry overview of study design and rationale
Scierka LE, Mena-Hurtado C, Shishehbor MH, Spertus JA, Nagpal S, Babrowski T, Bunte MC, Politano A, Humphries M, Chung J, Kirksey L, Alabi O, Soukas P, Parikh S, Faizer R, Fitridge R, Provance J, Romain G, McMillan N, Stone N, Scott K, Fuss C, Pacheco CM, Gosch K, Harper-Brooks A, Smolderen KG, Consortium O. The shifting care and outcomes for patients with endangered limbs – Critical limb ischemia (SCOPE-CLI) registry overview of study design and rationale. IJC Heart & Vasculature 2022, 39: 100971. PMID: 35198727, PMCID: PMC8850321, DOI: 10.1016/j.ijcha.2022.100971.Peer-Reviewed Original ResearchCritical limb ischemiaTreatment preferencesPeripheral artery diseaseProspective observational registryPatient-centered outcomesPatterns of carePoor wound healingHealth status outcomesProcess of careCLI careObservational registryLimb ischemiaPatient characteristicsArtery diseaseVascular centersVital statusMean agePatient preferencesPatient's perspectiveSevere formPatientsPsychosocial factorsStatus outcomesHealth statusCare experiences
2021
A new cure model accounting for extra non-cancer mortality: Validation and application to real data
Botta L, Goungounga J, Capocaccia R, Romain G, Colonna M, Gatta G, Boussari O, Jooste V. A new cure model accounting for extra non-cancer mortality: Validation and application to real data. Revue D'Epidémiologie Et De Santé Publique 2021, 69: s24. DOI: 10.1016/j.respe.2021.04.039.Peer-Reviewed Original ResearchRelative riskGeneral populationCancer-specific deathNon-cancer mortalityPatient's relative riskExtra riskCancer survivorsCancer patientsCure modelBreast cancerNet survivalRelative survivalOverall populationIndividual data analysisIndividual dataSame riskCure fractionCancer dataDeathPatientsRiskCancerMortalitySurvivalAge effectsFlexible Modeling of Net Survival and Cure by AML Subtype and Age: A French Population-Based Study from FRANCIM
Mounier M, Romain G, Callanan M, Alla A, Boussari O, Maynadié M, Colonna M, Jooste V. Flexible Modeling of Net Survival and Cure by AML Subtype and Age: A French Population-Based Study from FRANCIM. Journal Of Clinical Medicine 2021, 10: 1657. PMID: 33924506, PMCID: PMC8069423, DOI: 10.3390/jcm10081657.Peer-Reviewed Original ResearchTherapy-related AMLYounger patientsAML subtypesNet survivalAML patientsAcute myeloid leukemia diagnosisDiagnosis of AMLAcute myelomonocytic leukemiaAcute promyelocytic leukemiaYears of ageRecurrent cytogenetic abnormalitiesFrench populationMedian survivalMore patientsBetter prognosisPoor survivalAML subsetsMyelomonocytic leukemiaPromyelocytic leukemiaSex disparitiesPatientsOlder menCytogenetic abnormalitiesMonocytic leukemiaAge groups
2020
Cancer cure for 32 cancer types: results from the EUROCARE-5 study
Dal Maso L, Panato C, Tavilla A, Guzzinati S, Serraino D, Mallone S, Botta L, Boussari O, Capocaccia R, Colonna M, Crocetti E, Dumas A, Dyba T, Franceschi S, Gatta G, Gigli A, Giusti F, Jooste V, Minicozzi P, Neamtiu L, Romain G, Zorzi M, De Angelis R, Francisci S, Group T. Cancer cure for 32 cancer types: results from the EUROCARE-5 study. International Journal Of Epidemiology 2020, 49: 1517-1525. PMID: 32984907, DOI: 10.1093/ije/dyaa128.Peer-Reviewed Original ResearchConceptsConditional relative survivalCancer patientsProstate cancerCancer cureChronic lymphocytic leukemia patientsProportion of patientsThyroid cancer patientsEUROCARE-5 studyLymphocytic leukemia patientsSame death ratePopulation-based indicatorsMelanoma patientsPatients' qualityCorpus uteriFatal casesLung cancerPancreatic cancerThyroid cancerLeukemia patientsBreast cancerGeneral populationRelative survivalPatientsSkin melanomaAge 55
2019
Net survival in recurrence-free colon cancer patients
Drouillard A, Bouvier A, Boussari O, Romain G, Manfredi S, Lepage C, Faivre J, Jooste V. Net survival in recurrence-free colon cancer patients. Cancer Epidemiology 2019, 61: 124-128. PMID: 31212224, DOI: 10.1016/j.canep.2019.06.001.Peer-Reviewed Original ResearchConceptsRecurrence-free patientsNet survivalColon cancerPopulation-based digestive cancer registryConditional net survivalDigestive cancer registryStage III diseasePeriods of remissionEstimation of prognosisPrimary colon cancerColon cancer patientsRelevant clinical informationCancer RegistryClinical presentationCancer patientsCancer populationSurvivors' qualityClinical informationPatientsStage IStage IIIStage IIDiagnosisFlexible parametric modelsSurvivalTime-to-cure and cure proportion in solid cancers in France. A population based study
Romain G, Boussari O, Bossard N, Remontet L, Bouvier A, Mounier M, Iwaz J, Colonna M, Jooste V, Registries F. Time-to-cure and cure proportion in solid cancers in France. A population based study. Cancer Epidemiology 2019, 60: 93-101. PMID: 30933890, DOI: 10.1016/j.canep.2019.02.006.Peer-Reviewed Original ResearchConceptsTestis cancerCancer sitesThyroid cancerCure proportionFrench cancer registriesMost cancer sitesLarge national databaseHealthcare policy makersGynaecologic cancerYounger patientsCancer RegistryColorectal cancerSurvival cure modelUrinary tractCancer careDigestive cancersSolid cancersSkin melanomaSolid tumorsSmall intestineCancerPatientsNational databaseBreastCure
2018
A new approach to estimate time-to-cure from cancer registries data
Boussari O, Romain G, Remontet L, Bossard N, Mounier M, Bouvier A, Binquet C, Colonna M, Jooste V. A new approach to estimate time-to-cure from cancer registries data. Cancer Epidemiology 2018, 53: 72-80. PMID: 29414635, DOI: 10.1016/j.canep.2018.01.013.Peer-Reviewed Original ResearchConceptsPopulation-based cancer dataFlexible parametric cure modelsThyroid cancer patientsCancer registry dataParametric cure modelsCancer RegistryColorectal cancerCancer patientsPancreatic cancerCancer sitesBreast cancerRegistry dataCure modelAge groupsCancerCureDiagnosisSurvival frameworkCure fractionPatientsHealth insurance premiumsFrench networkSurvival time distributionYears
2017
Outcomes following polypectomy for malignant colorectal polyps are similar to those following surgery in the general population
Lopez A, Bouvier A, Jooste V, Cottet V, Romain G, Faivre J, Manfredi S, Lepage C. Outcomes following polypectomy for malignant colorectal polyps are similar to those following surgery in the general population. Gut 2017, 68: 111. PMID: 29074726, DOI: 10.1136/gutjnl-2016-312093.Peer-Reviewed Original ResearchConceptsSessile malignant polypsColorectal malignant polypsMalignant polypsPathological marginsEndoscopic resectionSurgical resectionRecurrence rateGeneral populationAge-standardised incidence ratesFive-year net survivalAge-standardised incidenceCumulative recurrence ratePopulation-based studyMalignant colorectal polypsTransanal resectionIncidence rateResectionColorectal polypsNet survivalPatientsSurvival analysisSurgeryPolypectomyTime trendsOutcomes